66 When compared with danazol, MMB showed a trend toward improved survival up to week 24 in the MOMENTUM trial. 55 In contrast, PAC- and BAT (best available therapy)–treated patients had similar survival in the very low–platelets setting. 67 Management of splenomegaly in patients with pretreatment thrombocytopenia Of note, no specific treatment for improving platelet count is available.
1
—
—